Investors in biomedical stocks are a tough crowd. They want to see current revenue streams and a pipeline of large-market products. Unfortunately Focal Inc. provided neither to a sufficient degree. Although it has a promising bioresorbable polymer with many potential applications in surgery and drug delivery and more than 70 issued patents, when it came to executing on products, Focal's story was "too little too late."
Focal stock, which traded at $18 per share soon after its IPO in 1997 [See Deal], rarely went north...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?